Italy Pierluigi Petrone outlines family-owned Petrone Group’s wide-range of outsourcing services to the pharmaceutical industry, how its international footprint has evolved over time, and his key priorities as president of Italy’s main primary pharma distribution association, ASSORAM. My dream is that Italy, thanks to its infrastructure and location, can become…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
India The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to 19 Indian pharmaceutical firms for the generic version of Pfizer’s oral antiviral COVID-19 pill. COVID-19 vaccine booster shots now…
Japan A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for its Niemann-Pick types A/B and B medicine in Japan, and the prospect of domestically developed COVID-19 vaccines being rolled out…
Germany The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case for broader use of its diabetes drug. Bayer’s 2021 annual report: €44.1 billion revenue, Crop Science grows double digits,…
Europe A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’ shuttering of its US R&D footprint. BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029:…
China The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in major Chinese cities, and the Chinese firms at risk of being delisted in the US if they do not hand…
LatAm The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s vaccine and approval of three new cannabis-based products. Moderna partners with Latin American Pharma https://endpts.com/covid-19-roundup-scottish-government-invests-27m-in-valnevas-covid-19-manufacturing-moderna-partners-with-latin-american-pharma/ In a move to…
APAC The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well as highlights from Indonesia, the Philippines, and Malaysia Singapore medicines regulator world’s first to achieve highest maturity level in…
Italy In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader, post-COVID changes to the pharma industry, and the state of private-public relationships in Europe. Furthermore, d’Alissac touches on the responsibility…
Spain Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the COVID-19 pandemic and the importance of new investment to increase Spain’s generic production capabilities. In addition, he outlines specific policy…
China A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair competition in the domestic industry; and US FDA concerns about the applicability of Chinese clinical trial results for the US…
See our Cookie Privacy Policy Here
